RxDoctor Payments Data

Thomas Judge, MD

Gastroenterology · Mount Laurel, NJNPI 1407945462

Payments from drug & device makers

$1,831in general payments, 2019–2025

Across 94 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$661
  • Takeda Pharmaceuticals U.S.A., Inc.$306
  • Bristol Myers Squibb$238
  • Medtronic$126
  • Gilead$118
  • Pfizer$73
  • plus $308 from 10 others

What the payments were for

  • Food & beverage$1,77399%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,831 in reported general payments places this provider in the 40th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$104,652
Medicare patients
485
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab96$2,563,380
Skyrizi On-BodyRisankizumab-Rzaa33$679,945
EntyvioVedolizumab39$334,728
Humira(Cf) PenAdalimumab24$230,432
RinvoqUpadacitinib17$132,475
RemicadeInfliximab18$126,204
CreonLipase/Protease/Amylase35$105,293
Cimzia (2 Pack)Certolizumab Pegol12$65,622
XifaxanRifaximin13$36,920
LinzessLinaclotide52$34,187
ViberziEluxadoline11$23,262
Mesalamine27$8,974
Lubiprostone27$4,509
Famotidine210$2,623
Omeprazole208$2,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$48$2,689,584114 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$306$334,72839 claims
AbbVieRinvoq, Creon, Linzess, Viberzi$661$295,217115 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$30$36,92013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Mount Laurel

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →